Current Infectious Disease Reports

, Volume 15, Issue 6, pp 600–611 | Cite as

Central Nervous System Infections in Travelers

CENTRAL NERVOUS SYSTEM (J LYONS, SECTION EDITOR)
  • 149 Downloads

Abstract

International travelers commonly contract infections while abroad, many of which are primary neurological diseases or have potential neurological sequelae. The implications of these neuroinfectious diseases extend beyond the individual, since returning travelers may contribute to the spread of infection in novel areas. In this review, we discuss signs, symptoms, treatments, and prophylaxes for these infections, as well as emerging trends with regard to neuroinfectious diseases of the returning traveler.

Keywords

Travel Central nervous system infection Encephalitis Meningitis Malaria Dengue Chikungunya Rabies Sleeping sickness 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Hannah Kirsch, Kiran T Thakur, and Gretchen Birbeck declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    •• Leder K, Torresi J, Libman MD, et al. GeoSentinel surveillance of illness in returned travelers, 2007–2011. Ann intern med. 2013;158(6):456–68. Using data from approximately 42,000 travelers presenting to travel or tropical medicine clinics, this GeoSentinel study elucidates patterns of disease contracted by travelers to numerous abroad sites.Google Scholar
  2. 2.
    Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl j med. 2005;353(9):924–32.PubMedGoogle Scholar
  3. 3.
    Chen LH, Wilson ME. Dengue and chikungunya infections in travelers. Curr opin infect dis. 2010;23(5):438–44.PubMedGoogle Scholar
  4. 4.
    Jelinek T. Dengue fever in international travelers. Clin infect dis off publ Infect Dis Soc Am. 2000;31(1):144–7.Google Scholar
  5. 5.
    Tuiskunen A, Hjertqvist M, Vene S, Lundkvist A. Dengue fever in returned Swedish travelers from Thailand. Infect ecol epidemiol. 2011;1.Google Scholar
  6. 6.
    Wichmann O, Gascon J, Schunk M, et al. Severe dengue virus infection in travelers: risk factors and laboratory indicators. J infect dis. 2007;195(8):1089–96.PubMedGoogle Scholar
  7. 7.
    Streit JA, Yang M, Cavanaugh JE, Polgreen PM. Upward trend in dengue incidence among hospitalized patients, United States. Emerg infec dis. 2011;17(5):914–6.Google Scholar
  8. 8.
    Amarasinghe A, Wichmann O, Margolis HS, Mahoney RT. Forecasting dengue vaccine demand in disease endemic and non-endemic countries. Hum vaccines. 2010;6(9).Google Scholar
  9. 9.
    Chastel C. Eventual role of asymptomatic cases of dengue for the introduction and spread of dengue viruses in non-endemic regions. Front physiol. 2012;3:70.PubMedGoogle Scholar
  10. 10.
    Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of dengue infection. Lancet. 2000;355(9209):1053–9.PubMedGoogle Scholar
  11. 11.
    Misra UK, Kalita J, Syam UK, Dhole TN. Neurological manifestations of dengue virus infection. J neurol sci. 2006;244(1–2):117–22.PubMedGoogle Scholar
  12. 12.
    Wasay M, Channa R, Jumani M, Shabbir G, Azeemuddin M, Zafar A. Encephalitis and myelitis associated with dengue viral infection clinical and neuroimaging features. Clin neurol neurosurg. 2008;110(6):635–40.PubMedGoogle Scholar
  13. 13.
    Larik A, Chiong Y, Lee LC, Ng YS. Longitudinally extensive transverse myelitis associated with dengue fever. BMJ case rep. 2012;2012.Google Scholar
  14. 14.
    Gutch M, Agarwal A, Amar A. Hypokalemic quadriparesis: an unusual manifestation of dengue fever. J nat sci biol med. 2012;3(1):81–3.PubMedGoogle Scholar
  15. 15.
    Ratnayake EC, Shivanthan C, Wijesiriwardena BC. Diaphragmatic paralysis: a rare consequence of dengue fever. BMC infect dis. 2012;12:46.PubMedGoogle Scholar
  16. 16.
    Huhtamo E, Hasu E, Uzcategui NY, et al. Early diagnosis of dengue in travelers: comparison of a novel real-time RT-PCR, NS1 antigen detection and serology. J clin virol off publ Pan Am Soc Clin Virol. 2010;47(1):49–53.Google Scholar
  17. 17.
    Moi ML, Ujiie M, Takasaki T, Kurane I. Dengue virus infection in travellers returning from Benin to France, July - August, 2010. Euro surveill bull Europeen sur les maladies transmissibles = Eur commun dis bull. 2010;15(39):19674.Google Scholar
  18. 18.
    Moi ML, Omatsu T, Tajima S, et al. Detection of dengue virus nonstructural protein 1 (NS1) by using ELISA as a useful laboratory diagnostic method for dengue virus infection of international travelers. J travel med. 2013;20(3):185–93.PubMedGoogle Scholar
  19. 19.
    Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559–67.PubMedGoogle Scholar
  20. 20.
    Thomas SJ, Eckels KH, Carletti I, et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am j trop med hygiene. 2013;88(1):73–88.Google Scholar
  21. 21.
    Sun W, Eckels KH, Putnak JR, et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J infect dis. 2013;207(5):700–8.PubMedGoogle Scholar
  22. 22.
    Oya A, Kurane I. Japanese encephalitis for a reference to international travelers. J travel med. 2007;14(4):259–68.PubMedGoogle Scholar
  23. 23.
    Fischer M, Lindsey N, Staples JE, Hills S, Centers for Disease C, Prevention. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm rep Morb mortal wkly rep Recomm rep Cent Dis Control. 2010;59(RR-1):1–27.Google Scholar
  24. 24.
    Buhl MR, Lindquist L. Japanese encephalitis in travelers: review of cases and seasonal risk. J travel med. 2009;16(3):217–9.PubMedGoogle Scholar
  25. 25.
    Hatz C. Editorial commentary: boosting Japanese encephalitis vaccine. Clin infect dis off publ Infect Dis Soc Am. 2012;55(6):835–6.Google Scholar
  26. 26.
    Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973–2008. Am j trop med hyg. 2010;82(5):930–6.PubMedGoogle Scholar
  27. 27.
    Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Japanese encephalitis. J neurol neurosurg psychiatr. 2000;68(4):405–15.PubMedGoogle Scholar
  28. 28.
    Ghosh D, Basu A. Japanese encephalitis-a pathological and clinical perspective. PLoS negl trop dis. 2009;3(9):e437.PubMedGoogle Scholar
  29. 29.
    Kalita J, Misra UK. Comparison of CT scan and MRI findings in the diagnosis of Japanese encephalitis. J neurol sci. 2000;174(1):3–8.PubMedGoogle Scholar
  30. 30.
    Verma R. MRI features of Japanese encephalitis. BMJ case rep. 2012;2012.Google Scholar
  31. 31.
    Duffy MR, Reed C, Edelson PJ, et al. A survey of US travelers to Asia to assess compliance with recommendations for the use of Japanese encephalitis vaccine. J travel med. 2013;20(3):165–70.PubMedGoogle Scholar
  32. 32.
    Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS pathog. 2007;3(12):e201.PubMedGoogle Scholar
  33. 33.
    Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. Chikungunya: a re-emerging virus. Lancet. 2012;379(9816):662–71.PubMedGoogle Scholar
  34. 34.
    Zayed A, Awash AA, Esmail MA, et al. Detection of Chikungunya virus in Aedes aegypti during 2011 outbreak in Al Hodayda, Yemen. Acta trop. 2012;123(1):62–6.PubMedGoogle Scholar
  35. 35.
    Chowdhury FI, Kabir A, Das A, Mukerrama SM, Masud S. Chikungunya fever: an emerging threat to Bangladesh. J Med. 2012;13(1):60–4.Google Scholar
  36. 36.
    Kularatne SA, Weerasinghe SC, Gihan C, et al. Epidemiology, clinical manifestations, and long-term outcomes of a major outbreak of chikungunya in a hamlet in sri lanka, in 2007: a longitudinal cohort study. J trop med. 2012;2012:639178.PubMedGoogle Scholar
  37. 37.
    Wu D, Wu J, Zhang Q, et al. Chikungunya outbreak in Guangdong Province, China, 2010. Emerg infect dis. 2012;18(3):493–5.PubMedGoogle Scholar
  38. 38.
    Centers for Disease C, Prevention. Chikungunya outbreak--Cambodia, February-March 2012. MMWR Morb mortal wkly rep. 2012;61:737–40.Google Scholar
  39. 39.
    Gibney KB, Fischer M, Prince HE, et al. Chikungunya fever in the United States: a fifteen year review of cases. Clin infect dis off publ Infect Dis Soc Am. 2011;52(5):e121–6.Google Scholar
  40. 40.
    Parola P, de Lamballerie X, Jourdan J, et al. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg infect dis. 2006;12(10):1493–9.PubMedGoogle Scholar
  41. 41.
    Jaffar-Bandjee MC, Das T, Hoarau JJ, et al. Chikungunya virus takes centre stage in virally induced arthritis: possible cellular and molecular mechanisms to pathogenesis. Microbes infect Inst Pasteur. 2009;11(14–15):1206–18.Google Scholar
  42. 42.
    Moro ML, Grilli E, Corvetta A, et al. Long-term chikungunya infection clinical manifestations after an outbreak in Italy: a prognostic cohort study. J infect. 2012;65(2):165–72.PubMedGoogle Scholar
  43. 43.
    Das T, Jaffar-Bandjee MC, Hoarau JJ, et al. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog neurobiol. 2010;91(2):121–9.PubMedGoogle Scholar
  44. 44.
    Lemant J, Boisson V, Winer A, et al. Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005–2006. Crit care med. 2008;36(9):2536–41.PubMedGoogle Scholar
  45. 45.
    Schilte C, Staikovsky F, Couderc T, et al. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS negl trop dis. 2013;7(3):e2137.PubMedGoogle Scholar
  46. 46.
    Tournebize P, Charlin C, Lagrange M. Neurological manifestations in Chikungunya: about 23 cases collected in Reunion Island. Rev neurol. 2009;165(1):48–51.PubMedGoogle Scholar
  47. 47.
    Gasque P. Chikungunya Virus Infection. In: Jackson AC, editor. Viral Infections of the Human Nervous System. Berlin: Springer; 2012.Google Scholar
  48. 48.
    Kee AC, Yang S, Tambyah P. Atypical chikungunya virus infections in immunocompromised patients. Emerg infect dis. 2010;16(6):1038–40.PubMedGoogle Scholar
  49. 49.
    Hatz CF, Kuenzli E, Funk M. Rabies: relevance, prevention, and management in travel medicine. Infect dis clin N Am. 2012;26(3):739–53.Google Scholar
  50. 50.
    Gautret P, Adehossi E, Soula G, et al. Rabies exposure in international travelers: do we miss the target? Int j infect dis IJID off publ Int Soc Infect Dis. 2010;14(3):e243–6.Google Scholar
  51. 51.
    Malerczyk C, Detora L, Gniel D. Imported human rabies cases in europe, the United States, and Japan, 1990 to 2010. J travel med. 2011;18(6):402–7.PubMedGoogle Scholar
  52. 52.
    Hemachudha T, Laothamatas J, Rupprecht CE. Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet neurol. 2002;1(2):101–9.PubMedGoogle Scholar
  53. 53.
    Warrell MJ. Intradermal Rabies Vaccination: The Evolution and Future of Pre- and Post-exposure Prophylaxis. In: Teunissen MBM, editor. Intradermal Immunization. Berlin: Springer; 2012. p. 139–57.Google Scholar
  54. 54.
    Wongsaroj P, Udomchaisakul P, Tepsumethanon S, Khawplod P, Tantawichien T. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis. Vaccine. 2013;31(13):1748–51.PubMedGoogle Scholar
  55. 55.
    Gautret P, Parola P. Rabies vaccination for international travelers. Vaccine. 2012;30(2):126–33.PubMedGoogle Scholar
  56. 56.
    Meslin FX. Rabies as a traveler's risk, especially in high-endemicity areas. J travel med. 2005;12 Suppl 1:S30–40.PubMedGoogle Scholar
  57. 57.
    Sakai H, Harun FM, Yamamoto N, Yuki N. Contamination with gangliosides in brain-derived rabies vaccine may trigger Guillain–Barre syndrome. J neurol neurosurg psychiatr. 2012;83(4):467–9.PubMedGoogle Scholar
  58. 58.
    Sudarshan MK, Mahendra BJ, Madhusudana SN, et al. An epidemiological study of animal bites in India: results of a WHO sponsored national multi-centric rabies survey. J commun dis. 2006;38(1):32–9.PubMedGoogle Scholar
  59. 59.
    Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ. 2005;83(5):360–8.PubMedGoogle Scholar
  60. 60.
    Ayele W, Fekadu M, Zewdie B, et al. Immunogenicity and efficacy of Fermi-type nerve tissue rabies vaccine in mice and in humans undergoing post-exposure prophylaxis for rabies in Ethiopia. Ethiop med j. 2001;39(4):313–21.PubMedGoogle Scholar
  61. 61.
    Wilde H, Tipkong P, Khawplod P. Economic issues in postexposure rabies treatment. J travel med. 1999;6(4):238–42.PubMedGoogle Scholar
  62. 62.
    Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine. 6/24/ 2009;27, Supplement 2(0):B13-B19.Google Scholar
  63. 63.
    Mueller JE, Gessner BD. A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt. Int j infect dis IJID off publ Int Soc Infect Dis. 2010;14(7):e553–9.Google Scholar
  64. 64.
    •• Kristiansen PA, Diomande F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin infect dis off publ Infect Dis Soc Am. 2013;56(3):354–63. This article shows that mass vaccination against serogroup A Neisseria meningitidis (NmA) in Burkina Faso eliminated NmA carriage in vaccinated districts and induced a herd-immunity effect against the pathogen.Google Scholar
  65. 65.
    Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. Lancet infect dis. 2007;7(12):797–803.PubMedGoogle Scholar
  66. 66.
    Dakar discussion group on priorities for research on epidemic meningococcal disease in A, Altmann D, Aseffa A, et al. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine. 2013;31(11):1453–1457.Google Scholar
  67. 67.
    Bilukha OO, Rosenstein N, National Center for Infectious Diseases CfDC, Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm rep Morb mortal wkly rep Recomm rep Cent Dis Control. 2005;54(RR-7):1–21.Google Scholar
  68. 68.
    Wilder-Smith A. Meningococcal disease: risk for international travellers and vaccine strategies. Travel med infect dis. 2008;6(4):182–6.PubMedGoogle Scholar
  69. 69.
    Hedberg ST, Fredlund H, Nicolas P, Caugant DA, Olcen P, Unemo M. Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives. Antimicrob agents chemother. 2009;53(4):1561–6.PubMedGoogle Scholar
  70. 70.
    Leimkugel J, Adams Forgor A, Gagneux S, et al. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J infect dis. 2005;192(2):192–9.PubMedGoogle Scholar
  71. 71.
    Standardized treatment of bacterial meningitis in Africa in epidemic and non epidemic situations. 2007.Google Scholar
  72. 72.
    van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693–702.PubMedGoogle Scholar
  73. 73.
    Thakur K, Zunt J. Neurologic parasitic infections in immigrants and travelers. Semin neurol. 2011;31(3):231–44.PubMedGoogle Scholar
  74. 74.
    Del Brutto OH. Neurocysticercosis among international travelers to disease-endemic areas. J travel med. 2012;19(2):112–7.PubMedGoogle Scholar
  75. 75.
    Leshem E, Kliers I, Bakon M, Gomori M, Karplus R, Schwartz E. Neurocysticercosis in travelers: a nation-wide study in Israel. J travel med. 2011;18(3):191–7.PubMedGoogle Scholar
  76. 76.
    Del Brutto OH, Nash TE, Garcia HH. Cysticerci-related single parenchymal brain enhancing lesions in non-endemic countries. J neurol sci. 2012;319(1–2):32–6.PubMedGoogle Scholar
  77. 77.
    Otte WM, Singla M, Sander JW, Singh G. Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. Neurology. 2013;80(2):152–62.PubMedGoogle Scholar
  78. 78.
    Simarro PP, Franco JR, Cecchi G, et al. Human African trypanosomiasis in non-endemic countries (2000–2010). J travel med. 2012;19(1):44–53.PubMedGoogle Scholar
  79. 79.
    Blum JA, Neumayr AL, Hatz CF. Human African trypanosomiasis in endemic populations and travellers. Eur j clin microbiol infect dis off publ Eur Soc Clin Microbiol. 2012;31(6):905–13.Google Scholar
  80. 80.
    Migchelsen SJ, Buscher P, Hoepelman AI, Schallig HD, Adams ER. Human African trypanosomiasis: a review of non-endemic cases in the past 20 years. Int j infect dis IJID off publ Int Soc Infect Dis. 2011;15(8):e517–24.Google Scholar
  81. 81.
    Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - do they really sleep? PLoS negl trop dis. 2011;5(11):e1358.PubMedGoogle Scholar
  82. 82.
    Kennedy PG. Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). Lancet neurol. 2013;12(2):186–94.PubMedGoogle Scholar
  83. 83.
    Diaz JH. Recognizing and reducing the risks of Chagas disease (American trypanosomiasis) in travelers. J travel med. 2008;15(3):184–95.PubMedGoogle Scholar
  84. 84.
    Pereira KS, Schmidt FL, Barbosa RL, et al. Transmission of chagas disease (American trypanosomiasis) by food. Adv food nutr res. 2010;59:63–85.PubMedGoogle Scholar
  85. 85.
    Oliveira-Filho J, Viana LC, Vieira-De-Melo RM, et al. Chagas disease is an independent risk factor for stroke - Baseline characteristics of a Chagas disease cohort. Stroke. 2005;36(9):2015–7.PubMedGoogle Scholar
  86. 86.
    Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta trop. 2010;115(1–2):22–7.PubMedGoogle Scholar
  87. 87.
    Loutan L. Malaria: still a threat to travellers. Int j antimicrob agents. 2003;21(2):158–63.PubMedGoogle Scholar
  88. 88.
    Kain KC, Keystone JS. Malaria in travelers. Epidemiology, disease, and prevention. Infect dis clin N Am. 1998;12(2):267–84.Google Scholar
  89. 89.
    Strickland GT. Fever in the returned traveler. Med clin N Am. 1992;76(6):1375–92.PubMedGoogle Scholar
  90. 90.
    O'Brien D, Tobin S, Brown GV, Torresi J. Fever in returned travelers: review of hospital admissions for a 3-year period. Clin infect dis off publ Infect Dis Soc Am. 2001;33(5):603–9.Google Scholar
  91. 91.
    Filler S, Causer LM, Newman RD, et al. Malaria surveillance–United States, 2001. Morb mortal wkly rep Surveill summ. 2003;52(5):1–14.Google Scholar
  92. 92.
    Mali S, Kachur SP, Arguin PM, et al. Malaria surveillance–United States, 2010. Morb mortal wkly rep Surveill summ. 2012;61(2):1–17.Google Scholar
  93. 93.
    World Malaria Report 2011. Geneva: World Health Organization;2011.Google Scholar
  94. 94.
    Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans Roy Soc Trop Med Hyg. 2000;94 Suppl 1:S1-90.Google Scholar
  95. 95.
    Varney NR, Roberts RJ, Springer JA, Connell SK, Wood PS. Neuropsychiatric sequelae of cerebral malaria in Vietnam veterans. J nerv ment dis. 1997;185(11):695–703.PubMedGoogle Scholar
  96. 96.
    Dugbartey AT, Dugbartey MT, Apedo MY. Delayed neuropsychiatric effects of malaria in Ghana. J nerv ment dis. 1998;186(3):183–6.PubMedGoogle Scholar
  97. 97.
    Roze E, Thiebaut MM, Mazevet D, et al. Neurologic sequelae after severe falciparum malaria in adult travelers. Eur neurol. 2001;46(4):192–7.PubMedGoogle Scholar
  98. 98.
    Nguyen TH, Day NP, Ly VC, et al. Post-malaria neurological syndrome. Lancet. 1996;348(9032):917–21.PubMedGoogle Scholar
  99. 99.
    Gilles HM. Management of Severe and Complicated Malaria: A Practical Handbook. Geneva: World Health Organization; 1991.Google Scholar
  100. 100.
    Praveen KAS, Subrahmanyam DKS. A rare cause of Guillain-Barre syndrome. Int J Nutr Pharm Neurol Dis. 2011;1(2):204–5.Google Scholar
  101. 101.
    Sokrab TE, Eltahir A, Idris MN, Hamid M. Guillain-Barre syndrome following acute falciparum malaria. Neurology. 2002;59(8):1281–3.PubMedGoogle Scholar
  102. 102.
    Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet neurol. 2005;4(12):827–40.PubMedGoogle Scholar
  103. 103.
    Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: strategies for risk groups. Clin microbiol rev. 2008;21(3):466–72.PubMedGoogle Scholar
  104. 104.
    Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411–25.PubMedGoogle Scholar
  105. 105.
    Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta trop. 2000;77(1):41–51.PubMedGoogle Scholar
  106. 106.
    Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl j med. 2002;346(16):1212–20.PubMedGoogle Scholar
  107. 107.
    Control CfD. Schistosomiasis FAQs. 2012. Accessed July 12, 2013, 2013.Google Scholar
  108. 108.
    Pittella JEH. Neuroschistosomiasis. In: Misra UD, Kalita J, Shakir RA, editors. Tropical Neurology. Georgetown: Landes Bioscience; 2003. p. 300–24.Google Scholar
  109. 109.
    Pittella JE. Neuroschistosomiasis. Brain pathol. 1997;7(1):649–62.PubMedGoogle Scholar
  110. 110.
    Pittella JEH. The Relation between Involvement of the Central-Nervous-System in Schistosomiasis-Mansoni and the Clinical Forms of the Parasitosis - a Review. J Trop Med Hyg. 1991;94(1):15–21.PubMedGoogle Scholar
  111. 111.
    McManus DP, Li Y, Gray DJ, Ross AG. Conquering 'snail fever': schistosomiasis and its control in China. Expert rev anti-infect ther. 2009;7(4):473–85.PubMedGoogle Scholar
  112. 112.
    Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. Immunol rev. 2004;201:156–67.PubMedGoogle Scholar
  113. 113.
    Ferrari TC. Spinal cord schistosomiasis. A report of 2 cases and review emphasizing clinical aspects. Medicine. 1999;78(3):176–90.PubMedGoogle Scholar
  114. 114.
    Clerinx J, van Gompel A, Lynen L, Ceulemans B. Early neuroschistosomiasis complicating Katayama syndrome. Emerg infect dis. 2006;12(9):1465–6.PubMedGoogle Scholar
  115. 115.
    Ferrari TCA, Moreira PRR, Cunha AS. Clinical characterization of neuroschistosomiasis due to Schistosoma mansoni and its treatment. Acta trop. 2008;108(2–3):89–97.PubMedGoogle Scholar
  116. 116.
    Carod-Artal FJ. Neurological complications of Schistosoma infection. Trans R Soc Trop Med Hyg. 2008;102(2):107–16.PubMedGoogle Scholar
  117. 117.
    Carod-Artal FJ. Neuroschistosomiasis. Expert rev anti-infective ther. 2010;8(11):1307–18.Google Scholar
  118. 118.
    Houdon L, Flodrops H, Rocaboy M, et al. Two Patients With Imported Acute Neuroschistosomiasis Due to Schistosoma mansoni. J travel med. 2010;17(4):274–7.PubMedGoogle Scholar
  119. 119.
    Jaureguiberry S, Ansart S, Perez L, Danis M, Bricaire F, Caumes E. Acute neuroschistosomiasis: two cases associated with cerebral vasculitis. Am j trop med hyg. 2007;76(5):964–6.PubMedGoogle Scholar
  120. 120.
    Sarazin M, Caumes E, Cohen A, Amarenco P. Multiple microembolic borderzone brain infarctions and endomyocardial fibrosis in idiopathic hypereosinophilic syndrome and in Schistosoma mansoni infestation. J neurol neurosurg psychiatr. 2004;75(2):305–7.PubMedGoogle Scholar
  121. 121.
    Devine MJ, Wilkinson PA, Doherty JF, Jarman PR. Neuroschistosomiasis presenting as brainstem encephalitis. Neurology. 2008;70(23):2262–4.PubMedGoogle Scholar
  122. 122.
    Hayashi M. Clinical features of cerebral schistosomiasis, especially in cerebral and hepatosplenomegalic type. Parasitol Int. 2003;52(4):375–83.PubMedGoogle Scholar
  123. 123.
    Ferrari TC, Moreira PR, Cunha AS. Spinal cord schistosomiasis: a prospective study of 63 cases emphasizing clinical and therapeutic aspects. J clin neurosci off j Neurosurg Soc Aust. 2004;11(3):246–53.Google Scholar
  124. 124.
    Moreno-Carvalho OA, Nascimento-Carvalho CM, Bacelar AL, et al. Clinical and cerebrospinal fluid (CSF) profile and CSF criteria for the diagnosis of spinal cord schistosomiasis. Arquivos de neuro-psiquiatria. 2003;61(2B):353–8.PubMedGoogle Scholar
  125. 125.
    Weller PF, Liu LX. Eosinophilic meningitis. Semin neurol. 1993;13(2):161–8.PubMedGoogle Scholar
  126. 126.
    Rachford FW. Potential intermediate and paratenic hosts for Angiostrongylus cantonensis. J parasitol. 1975;61(6):1117–9.PubMedGoogle Scholar
  127. 127.
    Wallace GD, Rosen L. Studies on eosinophilic meningitis. IV. Experimental infection of fresh-water and marine fish with Angiostrongylus cantonensis. Am j epidemiol. 1967;85(3):395–402.PubMedGoogle Scholar
  128. 128.
    Rosen L, Loison G, Laigret J, Wallace GD. Studies on eosinophilic meningitis. 3. Epidemiologic and clinical observations on Pacific islands and the possible etiologic role of Angiostrongylus cantonensis. Am j epidemiol. 1967;85(1):17–44.PubMedGoogle Scholar
  129. 129.
    Ash LR. Observations on the role of mollusks and planarians in the transmission of Angiostrongylus cantonensis infection to man in New Caledonia. Rev Biol Med. 1976;24(1):163–74.Google Scholar
  130. 130.
    Bowden DK. Eosinophilic meningitis in the New Hebrides: two outbreaks and two deaths. Am j trop med hyg. 1981;30(5):1141–3.PubMedGoogle Scholar
  131. 131.
    Punyagupta S, Juttijudata P, Bunnag T. Eosinophilic meningitis in Thailand. Clinical studies of 484 typical cases probably caused by Angiostrongylus cantonensis. Am j trop med hyg. 1975;24(6 Pt 1):921–31.PubMedGoogle Scholar
  132. 132.
    Kliks MM, Kroenke K, Hardman JM. Eosinophilic radiculomyeloencephalitis: an angiostrongyliasis outbreak in American Samoa related to ingestion of Achatina fulica snails. Am j trop med hyg. 1982;31(6):1114–22.PubMedGoogle Scholar
  133. 133.
    Kuberski T, Wallace GD. Clinical manifestations of eosinophilic meningitis due to Angiostrongylus cantonensis. Neurology. 1979;29(12):1566–70.PubMedGoogle Scholar
  134. 134.
    Kuberski T. Angiostrongyliasis. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens, and practice. 2nd ed. Philadelphia: Elsevier Churchill Livingston; 2006. p. 1225–30.Google Scholar
  135. 135.
    Lv S, Zhang Y, Steinmann P, Zhou XN. Emerging angiostrongyliasis in Mainland China. Emerg infect dis. 2008;14(1):161–4.PubMedGoogle Scholar
  136. 136.
    Kliks MM, Palumbo NE. Eosinophilic meningitis beyond the Pacific Basin: the global dispersal of a peridomestic zoonosis caused by Angiostrongylus cantonensis, the nematode lungworm of rats. Soc sci med. 1992;34(2):199–212.PubMedGoogle Scholar
  137. 137.
    Slom TJ, Cortese MM, Gerber SI, et al. An outbreak of eosinophilic meningitis caused by Angiostrongylus cantonensis in travelers returning from the Caribbean. N Engl j med. 2002;346(9):668–75.PubMedGoogle Scholar
  138. 138.
    Malvy D, Ezzedine K, Receveur MC, et al. Cluster of eosinophilic meningitis attributable to Angiostrongylus cantonensis infection in French policemen troop returning from the Pacific Islands. Travel med infect dis. 2008;6(5):301–4.PubMedGoogle Scholar
  139. 139.
    Graeff-Teixeira C. Expansion of Achatina fulica in Brazil and potential increased risk for angiostrongyliasis. Trans R Soc Trop Med Hyg. 2007;101(8):743–4.PubMedGoogle Scholar
  140. 140.
    New D, Little MD, Cross J. Angiostrongylus cantonensis infection from eating raw snails. N Engl j med. 1995;332(16):1105–6.PubMedGoogle Scholar
  141. 141.
    Markell EK, John DT, Krotoski WA. The blood– and tissue-dwelling nematodes. In: Markell EK, John DT, Krotoski WA, editors. Markell and Voge’s medical parasitology. 8th ed. Philadelphia: W.B. Saunders Compan; 1999.Google Scholar
  142. 142.
    Punyagupta S, Bunnag T, Juttijudata P, Rosen L. Eosinophilic meningitis in Thailand. Epidemiologic studies of 484 typical cases and the etiologic role of Angiostrongylus cantonensis. Am j trop med hyg. 1970;19(6):950–8.PubMedGoogle Scholar
  143. 143.
    Yii CY. Clinical observations on eosinophilic meningitis and meningoencephalitis caused by Angiostrongylus cantonensis on Taiwan. Am j trop med hyg. 1976;25(2):233–49.PubMedGoogle Scholar
  144. 144.
    Moore DA, McCroddan J, Dekumyoy P, Chiodini PL. Gnathostomiasis: an emerging imported disease. Emerg infect dis. 2003;9(6):647–50.PubMedGoogle Scholar
  145. 145.
    Punyagupta S, Limtrakul C, Vichipanthu P, Karnchanachetanee C, Nye SW. Radiculomyeloencephalitis associated with eosinophilic pleocytosis. Report of nine cases. Am j trop med hyg. 1968;17(4):551–60.PubMedGoogle Scholar
  146. 146.
    Diaz JH. Recognizing and reducing the risks of helminthic eosinophilic meningitis in travelers: differential diagnosis, disease management, prevention, and control. J travel med. 2009;16(4):267–75.PubMedGoogle Scholar
  147. 147.
    Pai PJ, Blackburn BG, Kazacos KR, Warrier RP, Begue RE. Full recovery from Baylisascaris procyonis eosinophilic meningitis. Emerg infect dis. 2007;13(6):928–30.PubMedGoogle Scholar
  148. 148.
    Gavin PJ, Kazacos KR, Tan TQ, et al. Neural larva migrans caused by the raccoon roundworm Baylisascaris procyonis. Pediatr infect dis j. 2002;21(10):971–5.PubMedGoogle Scholar
  149. 149.
    Cunningham CK, Kazacos KR, Mcmillan JA, et al. Diagnosis and Management of Baylisascaris-Procyonis Infection in an Infant with Nonfatal Meningoencephalitis. Clin Infect Dis. 1994;18(6):868–72.PubMedGoogle Scholar
  150. 150.
    Kazacos KR, Gavin PJ, Shulman ST, et al. Raccoon roundworm encephalitis - Chicago, Illinois, and Los Angeles, California, 2000 (Reprinted from MMWR, vol 50, pg 1153, 2002). Jama-J Am Med Assoc. 2002;287(5):580–1.Google Scholar
  151. 151.
    Park SY, Glaser C, Murray WJ, et al. Raccoon roundworm (Baylisascaris procyonis) encephalitis: case report and field investigation. Pediatrics. 2000;106(4):E56.PubMedGoogle Scholar
  152. 152.
    Murray WJ, Kazacos KR. Raccoon roundworm encephalitis. Clin infect dis off publ Infect Dis Soc Am. 2004;39(10):1484–92.Google Scholar
  153. 153.
    Nelson CA, Zunt JR. Tuberculosis of the central nervous system in immunocompromised patients: HIV infection and solid organ transplant recipients. Clin infect dis off publ Infect Dis Soc Am. 2011;53(9):915–26.Google Scholar
  154. 154.
    Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin infect dis off publ Infect Dis Soc Am. 2010;50 Suppl 3:S223–30.Google Scholar
  155. 155.
    Asano T, Kawamoto H, Asakuma J, Tanimoto T, Kobayashi H, Hayakawa M. Paradoxical worsening of tuberculosis after anti-TB therapy in a kidney transplant recipient. Transplant proc. 2000;32(7):1960–2.PubMedGoogle Scholar
  156. 156.
    Wells CD. Global Impact of Multidrug-Resistant Pulmonary Tuberculosis Among HIV-Infected and Other Immunocompromised Hosts: Epidemiology, Diagnosis, and Strategies for Management. Curr infect dis rep. 2010;12(3):192–7.PubMedGoogle Scholar
  157. 157.
    Lynch K, Farrell M. Cerebral tuberculoma in a patient receiving anti-TNF alpha (adalimumab) treatment. Clin rheumatol. 2010;29(10):1201–4.PubMedGoogle Scholar
  158. 158.
    Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin microbiol rev. 2012;25(2):264–96.PubMedGoogle Scholar
  159. 159.
    Petersen E, Kijlstra A, Stanford M. Epidemiology of ocular toxoplasmosis. Ocul immunol inflamm. 2012;20(2):68–75.PubMedGoogle Scholar
  160. 160.
    Ekman CC, Chiossi MF, Meireles LR, et al. Case–control study of an outbreak of acute toxoplasmosis in an industrial plant in the state of Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo. 2012;54(5):239–44.PubMedGoogle Scholar
  161. 161.
    Lortholary O, Charlier C, Lebeaux D, Lecuit M, Consigny PH. Fungal infections in immunocompromised travelers. Clin infect dis off publ Infect Dis Soc Am. 2013;56(6):861–9.Google Scholar
  162. 162.
    Norman FF, López-Vélez R. Prevention of Tropical and Parasitic Infections: The Immunocompromised Traveler. In: Safdar A, editor. Principles and Practice of Cancer Infectious Diseases. Berlin: Springer; 2011. p. 551–60.Google Scholar
  163. 163.
    Wieten RW, Leenstra T, Goorhuis A, van Vugt M, Grobusch MP. Health risks of travelers with medical conditions–a retrospective analysis. J travel med. 2012;19(2):104–10.PubMedGoogle Scholar
  164. 164.
    Chang F, Prytherch H, Nesbitt RC, Wilder-Smith A. HIV-related travel restrictions: trends and country characteristics. Global health action. 2013;6:20472.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.New York University School of MedicineNew YorkUSA
  2. 2.Department of NeurologyJohns Hopkins HospitalBaltimoreUSA
  3. 3.Department of NeurologyUniversity of Rochester School of MedicineRochesterUSA

Personalised recommendations